カテゴリ： GlobalData, アメリカ, 企業調査

Proteostasis Therapeutics Inc (PTI)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Proteostasis Therapeutics Inc (PTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9816
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：66
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Proteostasis Therapeutics Inc (Proteostasis) is a developer of therapies that discovers and develops therapeutics for the treatment of diseases related to defects in protein folding, trafficking and clearance. The company’s portfolio spans drug candidates for cystic fibrosis, neurodegeneration and protein conformational diseases. Proteostasis employs Disease Relevant Translation platform that combines proteomics, genomics, and functional assays with medicinal chemistry and systems biology to discover novel drugs for disorders such as Alzheimer’s disease, Huntington’s disease, and Parkinson’s disease. PTI is headquartered in Cambridge, Massachusetts, the US.

Proteostasis Therapeutics Inc (PTI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Proteostasis Therapeutics Raises USD37 Million in Series B Financing 12
Proteostasis Therapeutics Raises USD22 Million in Venture Financing 14
Proteostasis Therapeutics Raises Additional USD2 Million in Venture Financing 15
Proteostasis Therapeutics Raises USD3 Million in Venture Financing 16
Partnerships 17
Basilea Pharma Enters into Agreement with Adult Brain Tumor Consortium 17
Basilea Pharmaceutica International Enters into Agreement with Biomedical Advanced Research and Development Authority 18
Proteostasis Therapeutics Amends Research Agreement with Astellas Pharma 19
Proteostasis Therapeutics Extends Co-Development Agreement With Cystic Fibrosis Foundation Therapeutics 20
Proteostasis Therapeutics Enters Into Co-Development Agreement With Scripps Research Institute 21
Proteostasis Therapeutics Enters into Co-Development Agreement with Cystic Fibrosis Foundation Therapeutics 22
Licensing Agreements 23
Grupo Biotoscana Enters into Licensing Agreement with Basilea Pharma 23
Basilea Pharma Enters into Licensing Agreement with Asahi Kasei Pharma 24
Hikma Pharma Extends its Distribution Agreement with Basilea Pharma 25
Basilea Pharmaceutical Amends Terms of Licensing Agreement with Stiefel Labs for Toctino 26
Dotmatics Enters Into Licensing Agreement With Basilea Pharma For Pre-Clinical Research Informatics 27
Equity Offering 28
Proteostasis Therapeutics Prices Public Offering of Shares for USD74.3 Million 28
Proteostasis Therapeutics to Raise USD50 Million in Public Offering of Shares 30
Proteostasis Therapeutics Withdraws Public Offering of Shares for USD65.6 Million 31
Proteostasis Therapeutics Raises USD46 Million in Public Offering of Shares 33
Proteostasis Therapeutics Raises USD65 Million in Public Offering of Shares 35
Proteostasis Therapeutics Inc – Key Competitors 37
Proteostasis Therapeutics Inc – Key Employees 38
Proteostasis Therapeutics Inc – Locations And Subsidiaries 39
Head Office 39
Recent Developments 40
Financial Announcements 40
Mar 14, 2018: Proteostasis Therapeutics Announces Fourth Quarter and Year-End 2017 Financial Results 40
Nov 14, 2017: Proteostasis Therapeutics Reports Third Quarter 2017 Results and Provides CF Portfolio Update 43
Mar 30, 2017: Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update 45
Corporate Communications 47
Jul 31, 2017: Proteostasis Appoints Helen M. Boudreau as Chief Financial Officer 47
Feb 27, 2017: Basilea proposes Dr. Nicole Onetto as new member of the Board of Directors 48
Product News 49
12/11/2017: Proteostasis Therapeutics Announces Positive Clinical Results from Studies of PTI-801 in Healthy Volunteers and Patients with Cystic Fibrosis 49
Oct 31, 2017: Proteostasis Therapeutics Focuses on Research and Development of CF Drug Candidates and Astellas Pharma Collaboration Programs 50
07/31/2017: Proteostasis Therapeutics Provides Update on Development of PTI-428 51
07/31/2017: Proteostasis Therapeutics Provides Update on Development of PTI-801 52
03/12/2018: Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy Designation for PTI-428 in Cystic Fibrosis 53
01/08/2018: Proteostasis Proprietary Triple Combination Therapy Study Protocol Receives Endorsement and High Strategic Fit Score from the Largest Cystic Fibrosis Patient Advocacy Groups in the U.S. and Europe 54
Product Approvals 55
Apr 04, 2018: Proteostasis Therapeutics Receives FDA Fast Track Designation for Triple Combination Program in Patients with Cystic Fibrosis 55
Mar 14, 2018: Proteostasis Therapeutics Announces FDA Grants Orphan Drug Designation for PTI-428 in Cystic Fibrosis 56
Jun 23, 2017: Proteostasis Therapeutics Files Investigational New Drug Application for PTI-808, Cystic Fibrosis Potentiator 57
Clinical Trials 58
Dec 11, 2017: Proteostasis Therapeutics Announces Positive Clinical Results from Studies of PTI-428 in Healthy Volunteers and Patients with Cystic Fibrosis 58
Dec 11, 2017: Proteostasis Therapeutics Announces Positive Clinical Results from Studies of PTI-808 in Healthy Volunteers and Patients with Cystic Fibrosis 59
Jul 31, 2017: Proteostasis Therapeutics Provides Update on Development of PTI-808 60
Jun 29, 2017: Proteostasis Therapeutics Reports Preliminary Data from Phase 1 Study of PTI-428 in Patients with Cystic Fibrosis 61
Jun 07, 2017: Proteostasis Therapeutics Announces Clinical and Regulatory Progress Across Pipeline Programs 63
Jun 07, 2017: Proteostasis Therapeutics Announces Clinical Development Update on Cystic Fibrosis Drug Candidate PTI-801 64
Jun 07, 2017: Proteostasis Therapeutics Announces Update on Phase 1 Trial of PTI-808, CFTR potentiator 65
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66

List of Tables
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Proteostasis Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Proteostasis Therapeutics Raises USD37 Million in Series B Financing 12
Proteostasis Therapeutics Raises USD22 Million in Venture Financing 14
Proteostasis Therapeutics Raises Additional USD2 Million in Venture Financing 15
Proteostasis Therapeutics Raises USD3 Million in Venture Financing 16
Basilea Pharma Enters into Agreement with Adult Brain Tumor Consortium 17
Basilea Pharmaceutica International Enters into Agreement with Biomedical Advanced Research and Development Authority 18
Proteostasis Therapeutics Amends Research Agreement with Astellas Pharma 19
Proteostasis Therapeutics Extends Co-Development Agreement With Cystic Fibrosis Foundation Therapeutics 20
Proteostasis Therapeutics Enters Into Co-Development Agreement With Scripps Research Institute 21
Proteostasis Therapeutics Enters into Co-Development Agreement with Cystic Fibrosis Foundation Therapeutics 22
Grupo Biotoscana Enters into Licensing Agreement with Basilea Pharma 23
Basilea Pharma Enters into Licensing Agreement with Asahi Kasei Pharma 24
Hikma Pharma Extends its Distribution Agreement with Basilea Pharma 25
Basilea Pharmaceutical Amends Terms of Licensing Agreement with Stiefel Labs for Toctino 26
Dotmatics Enters Into Licensing Agreement With Basilea Pharma For Pre-Clinical Research Informatics 27
Proteostasis Therapeutics Prices Public Offering of Shares for USD74.3 Million 28
Proteostasis Therapeutics to Raise USD50 Million in Public Offering of Shares 30
Proteostasis Therapeutics Withdraws Public Offering of Shares for USD65.6 Million 31
Proteostasis Therapeutics Raises USD46 Million in Public Offering of Shares 33
Proteostasis Therapeutics Raises USD65 Million in Public Offering of Shares 35
Proteostasis Therapeutics Inc, Key Competitors 37
Proteostasis Therapeutics Inc, Key Employees 38

List of Figures
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Proteostasis Therapeutics Inc (PTI)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Stavropolenergosbyt (STSB)：電力：M&Aディール及び事業提携情報
    Summary Stavropolenergosbyt, a subsidiary of Novgorodskaya energosbytovaya kompaniya is an energy and power company that supplies and distributes electricity. The company provides services such as electricity distribution, energy survey, payment information, energy audit and inspection and energy sa …
  • HoMedics LLC：企業の戦略的SWOT分析
    HoMedics LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Acer Therapeutics Inc (ACER)：医療機器：M&Aディール及び事業提携情報
    Summary Acer Therapeutics Inc (Acer), formerly Opexa Therapeutics Inc is a pharmaceutical company that offers acquisition, development and commercialization of therapies for patients with serious rare diseases. The company offers treatment of autoimmune disorders, rheumatoid arthritis, diabetes and …
  • GEN energija, d.o.o.：企業の戦略的SWOT分析
    GEN energija, d.o.o. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Cohort Plc
    Cohort Plc - Strategy, SWOT and Corporate Finance Report Summary Cohort Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • AltaGas Ltd (ALA)：石油・ガス：M&Aディール及び事業提携情報
    Summary AltaGas Ltd (AltaGas) is an energy utility. The company undertakes activities related to extraction, transmission, distribution and storage of natural gas. AltaGas generates electricity utilizing diverse fuel sources, including wind, run-of-river hydro, geothermal and gas-fired generation pl …
  • Parkland Fuel Corp (PKI)：石油・ガス：M&Aディール及び事業提携情報
    Summary Parkland Fuel Corp (Parkland) is a downstream energy company. It markets various fuel and petroleum products, including gasoline, propane, lubricants, diesel, heating oil, and other petroleum products. The company maintains a portfolio of supply relationships, storage infrastructure, and thi …
  • Genome Institute of Singapore-医療機器分野：企業M&A・提携分析
    Summary Genome Institute of Singapore (GIS) is a research institute that provides various research programs and services in different areas. The institute concentrates on genomic sciences to improve public health and prosperity in Singapore. It handles the latest in technology and comprises early ca …
  • Yamana Gold Inc.：企業の戦略・SWOT・財務情報
    Yamana Gold Inc. - Strategy, SWOT and Corporate Finance Report Summary Yamana Gold Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Mallinckrodt, LLC-製薬・医療分野：企業M&A・提携分析
    Summary Mallinckrodt LLC (Mallinckrodt), a subsidiary of Mallinckrodt Plc is a biophramaceutical company that develops medicines. The company manufactures, markets and distributes generic and specialty pharmaceuticals, active pharmaceutical ingredients, diagnostic imaging agents, global medical imag …
  • HSC Technology Group Ltd (HSC)：企業の財務・戦略的SWOT分析
    HSC Technology Group Ltd (HSC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • NV Bekaert SA：企業の戦略・SWOT・財務情報
    NV Bekaert SA - Strategy, SWOT and Corporate Finance Report Summary NV Bekaert SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Aerie Pharmaceuticals Inc (AERI)：製薬・医療：M&Aディール及び事業提携情報
    Summary Aerie Pharmaceuticals Inc (Aerie) is a pharmaceutical company that discovers, develops and commercializes therapies for the treatment of patients with glaucoma and other diseases of the eye. The company’s product candidates comprise rhopressa, a once-daily eye drop which is used for the redu …
  • Piller Group GmbH：企業の戦略的SWOT分析
    Piller Group GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Orix Corporation
    Orix Corporation - Strategy, SWOT and Corporate Finance Report Summary Orix Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Hayleys PLC (HAYL.N0000)：企業の財務・戦略的SWOT分析
    Summary Hayleys plc (Hayleys) is a diversified company that offers consumer services. The company’s products include purification products, textiles and construction materials, among others. It offers services such as treasury unit, strategic business development unit, corporate communications, corp …
  • KFG Resources Ltd (KFG)：企業の財務・戦略的SWOT分析
    Summary KFG Resources Ltd (KFG) is a petroleum and natural gas exploration company that supplies natural gas. The company produces crude oil and natural gas through its reserves. Its oil and gas reserves are located in Mississippi, Wilcox, and Louisiana. KFG’s Mississippi’s projects comprise Carthag …
  • Cogentix Medical Inc (CGNT)：企業の財務・戦略的SWOT分析
    Summary Cogentix Medical Inc (Cogentix Medical), formerly Vision-Sciences Inc, is a medical device company that designs, develops, manufactures and markets fiberoptic and video endoscopy products. The company’s major products include PrimeSight endoscopy systems, Urgent PC neuromodulation system and …
  • Cloud Cap Technology Inc.：企業の戦略・SWOT・財務情報
    Cloud Cap Technology Inc. - Strategy, SWOT and Corporate Finance Report Summary Cloud Cap Technology Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • AMAG Pharmaceuticals Inc (AMAG)-製薬・医療分野：企業M&A・提携分析
    Summary AMAG Pharmaceuticals Inc (AMAG) is a biopharmaceutical company that develops and commercializes specialty pharmaceutical products. The company focuses on maternal health, anemia management and cancer supportive care. Its major products include Makena (hydroxyprogesterone caproate injection) …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆